[88] found that clear cell renal cell carcinoma (ccRCC) expressing MUC1 were characterized by metabolic reprogramming involving glucose and lipid metabolic pathways, and that inhibition of MUC1 expression reduced cell viability and survival rates and enhanced sensitivity to cisplatin. This evidence concerns the gene MUC1 and nonpapillary renal cell carcinoma.